Kornimate/medical-research-clean huggingface dataset:
non-invasive distractor during knee arthroscopy

Conditions: Knee Arthritis; Knee Arthropathy

Summary: patients will be prospectively recruited for knee joint distraction who are undergoing knee arthroscopy. patient demographics, operative factors, and rates of medical comorbidities will be collected and evaluated. intraoperative arthroscopic images will be evaluated by the attending orthopaedic surgeon with standard and testing mechanism and a measuring device will be used to measure the distance between the femur and tibia in the medial and lateral compartments.


Eligibility criteria:
inclusion criteria: * adults ≥ 18 years of age who have capacity to provide informed consent. eligible participants will include existing patients of dr. distefano who are scheduled to undergo knee arthroscopic surgery to address meniscal pathology. study risks, benefits and description will be provided and informed consent will be obtained. exclusion criteria: * patients with prior history of neurovascular deficiency or history of prior injury * patients with a prior history of knee surgery * patients with diagnosed knee ligament laxity or knee instability. * patients that are not cleared for knee arthroscopy

Keywords: arthroscopy knee joint distraction non invasive sports medicine
conteci program: a new way to control peripheral arterial disease using new technologies

Conditions: Peripheral Arterial Disease; Personal Satisfaction; Telemedicine

Summary: the current increase in chronic diseases calls for changes to the health system. it is necessary to promote expert patient in chronic disease. the expansion of new technologies gives us new tools to face new challenges, providing efficiency, expertise and autonomy. the characteristics of peripheral arterial disease make possible to promote expert patient and the self-management. in order to bring these concepts together the telemedicine program was created to promote expert patient for increasing the quality of life and satisfaction of patients and improving the efficiency of the health system. methods: randomized clinical trial on patients with peripheral arterial disease in intermittent claudication grade. they were randomized into two groups: intervention arm (ia) using conteci program for self-managing and control arm (ca), followed as usual vascular visits.


Eligibility criteria:
inclusion criteria: * patient with confirmed pad * over 18 years old * informed consent * internet access (patient or family) * spanish or catalan fluidity exclusion criteria: * cognitive impairment * previous patency arterial surgery * sever chronic obstructive pulmonary disease (gold iii/ iv) * patients with decreased survival of 12 months
effect of race/ethnicity and genes on acetaminophen pharmacokinetics

Conditions: Pain; Fever; Hepatotoxicity

Summary: although acetaminophen is the most commonly used nonprescription drug in the usa, little is known regarding the influence of genes and race/ethnicity on acetaminophen disposition. the investigators long-term goal is to understand the causes of differences in acetaminophen disposition between people that are the result of genetic variation and ethnicity and may predispose individuals to a higher risk of acetaminophen hepatotoxicity. the aim of this particular study is to measure the rate of elimination of acetaminophen via the 3 main pathways (glucuronidation, sulfation and oxidation) in self-identified white-americans (n=100) and african-americans (n=100). these rates will then be correlated with selected genetic polymorphisms in genes encoding enzymes involved in acetaminophen metabolism. two main hypotheses will be tested: 1. african-americans eliminate acetaminophen more rapidly by glucuronidation than do white-americans. 2. elimination via glucuronidation, sulfation, and oxidation in subjects will be significantly correlated with the presence of polymorphisms in the ugt1a6, sult1a1, and cyp2e1 genes, respectively.


Eligibility criteria:
inclusion criteria: * self-declared white/caucasian * self-declared african-american * active * ambulatory * no evidence of medical disease exclusion criteria: * alcohol use of 3 or more drinks per day * hiv or hepatitis (b or c) infection * isoniazid * disulfiram * phenobarbital * phenytoin * carbamazepine * rifampicin * valproic acid * probenecid * st. john's wort
inappropriate medications associated with anticholinesterase and/or memantine treatment in the elderly

Conditions: Alzheimer's Disease

Summary: in each of the 7 french areas that should be involved, patients aged 75 years and over from three different sectors will be included: the geriatric consultation unit (60%) and two kinds of nursing homes, private (20%) and state (10%). outpatients will be included in chronological order; patients in nursing homes will be included at random. the patients and their families will be asked about the treatments received on the day of inclusion. the inclusion period will extend over a year. the investigating practitioners will be asked to fill in a questionnaire reporting the main clinical data, adverse effects occurrence, and information on the treatment given.


Eligibility criteria:
inclusion criteria: * patients aged 75 years and over identified as having alzheimer disease and who have been treated for more than 3 months with anticholinesterase and/or memantine exclusion criteria: * patients with decompensated chronic condition or acute phase disease

Keywords: inappropriate medications associated alzheimer's disease
influence of nutrition and sarcopenia on esophageal cancer outcomes

Conditions: Esophageal Cancer; Sarcopenia

Summary: prospective multicenter longitudinal (observational) study recruiting from tertiary centers for the surgical management of esophageal cancer; virginia mason medical center (seattle, usa) and st mary's hospital (imperial college, london, uk). this is intended to be a pilot study.

patients undergoing curative treatment for esophageal cancer will be recruited at the time of routine clinical assessment shortly following initial diagnosis and will undergo clinical and radiological evaluation at two study time points: (1) staging investigation (e.g. laparoscopy or endoscopy) and (2) definitive surgical resection. study time points have been judiciously chosen to coincide with interventions that form part of patient's routine clinical care. it is intended that sampling will occur on the day of each intervention/surgery following a routine period of fasting.

Eligibility criteria:
inclusion criteria: * patients with the following characteristics will be eligible for inclusion in this study: * age 18-90 years * newly diagnosed (prior to treatment) with esophageal and/or gastroesophageal junctional cancer (adeno- or squamous cell carcinoma) * planning to undergo curative treatment, including surgical resection with or without neoadjuvant therapy exclusion criteria: * patients with the following characteristics will not be eligible for inclusion in this study: * pregnant females * without malignant esophageal disease * inability or unwillingness to provided informed written consent
pilot study of lisdexamfetamine for treatment of cocaine dependence

Conditions: Cocaine Dependence

Summary: the purpose of this study is to evaluate ideal dose or lisdexamfetamine and tolerability, plus reduction in cocaine use and craving.

evaluate ideal dose or lisdexamfetamine and tolerability, plus reduction in cocaine use and craving as determined by self-report and cocaine-positive urine samples.

Eligibility criteria:
.inclusion criteria: 1. men and women between the ages of 18-65 who meet diagnostic and statistical manual -iv criteria for current cocaine dependence 2. used cocaine at least four days in the past month 3. individuals must be in good general health 4. individuals must be capable of giving informed consent and capable of complying with study procedures 5. women of child-bearing age must agree to use a method of contraception with proven efficacy, consisting of one of the following: 1) any form of hormonal contraception; 2) intra-uterine device; 3) sterilization; 4) double-barrier contraception which is a combination of two of the following: condoms, spermicide, diaphragm. pregnancy tests will be performed monthly and if a woman becomes pregnant, the study medication will be discontinued. exclusion criteria: 1. individuals who meet dsm-iv-tr criteria for bipolar disorder, schizophrenia, or any psychotic disorder other than transient psychosis due to drug abuse 2. individuals with any other current axis i psychiatric disorder as defined by dsm-iv-tr that in the investigator's judgment are unstable, or would be disrupted by study medication, or are likely to require pharmacotherapy during the study period 3. individuals physiologically dependent on any other drugs (excluding nicotine or cannabis) which require medical intervention 4. individuals with current psychostimulant abuse or dependence (other than cocaine dependence) 5. individuals with current suicidal risk 6. individuals with coronary vascular disease as indicated by history or suspected by abnormal ecg or history of cardiac symptoms 7. unstable physical disorders which might make participation hazardous such as uncontrolled hypertension (sbp \> 140, diastolic blood pressure \> 90, or heart rate \> 100 when sitting quietly), acute hepatitis (patients with chronic mildly elevated transaminases (\< 3x upper limit of normal are acceptable), or uncontrolled diabetes 8. individuals with a history of seizures, hyperthyroidism and/or glaucoma 9. history of allergic reaction to study medication 10. women who are pregnant or nursing 11. currently being prescribed psychotropic medication by another physician (other than sleep medication) 12. individuals who are legally mandated (e.g., to avoid incarceration) to participate in substance abuse treatment program

Keywords: cocaine lisdexamfetamine vyvanse
nab-paclitaxel treatment in advanced squamous cell carcinoma of lung

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this trial is to study the efficacy of nab-pc vs. gc and evaluate toxicity of nab-pc in advanced squamous cell cancer of lung. the correlation between the efficacy of nab-pc and some biomarkers is also to be evaluated.

albumin-bound paclitaxel(nab-p) utilizes the albumin binding proteins,such as (gp60)/caveolin-1 (cav1) and sparc(secreted protein acidic and rich in cysteine), achieving high intratumoral paclitaxel accumulation. it is reported that cav1 is overexpressed in squamous cell cancer(sqc), so it is possible that nab-pc is more highly active than gc in sqc of lung.

Eligibility criteria:
inclusion criteria: * previously untreated, histological documented stage iiib (not amenable for radical regional therapy) or stage iv squamous cell carcinoma of lung. at least one measurable lesion as defined by recist criteria. * at least 18 years of age. * ecog ps 0\~1 * patients have no previously malignant tumor history except cured cervical carcinoma in situ, basal cell carcinoma or superficial bladder cancer. patients are also eligible if they have received a chemotherapy regimen as neoadjuvant or adjuvant chemotherapy and the disease recurred over 12 months since the finishing of neoadjuvant or adjuvant chemotherapy. * neutrophil ≥ 1.5 x 109 /l, hemoglobin \> 90 g/l, platelet count \> 100x109/l. * total bilirubin ≤ 1.5 x upper limit of normal. alt and ast \< 2.5 x upper limit of normal without liver metastasis, alt and ast \< 5 x upper limit of normal with liver metastasis. serum creatinine \< 1.5 x upper limit of normal. * urine pregnancy test is negative for woman. * estimated life expectancy is at least 3 months. * patient comply with the clinical trial protocal. * informed consent must be signed. exclusion criteria: * patients who are currently undergoing other anti-tumor therapy. * patients who was enrolled in any other clinical trial within 4 weeks of study entry. * any physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any study medication or render the subject at high risk from treatment. * central nervous system (cns) tumor or metastatic tumor. * serious mental disorder. * serious dysgnosia. * other serious comorbidity. * alcohol or drug dependence. * previously allergic to drugs used in the study.

Keywords: squamous cell carcinoma of lung albumin bound paclitaxel chemotherapy
cardiovascular rehabilitation - effectiveness of the tulppa program

Conditions: Coronary Heart Disease

Summary: this study investigates the effectiveness of a finnish tulppa outpatient rehabilitation program. tulppa is a group-based secondary prevention program for patients with vascular diseases. the program is developed by the finnish heart association. the intervention is implemented at the local primary health care centers in 12 health districts in finland. a longitudinal controlled study is used to investigate the effects of the intervention on participants' level of cardiovascular risk factors (e.g. lipids, blood pressure, body mass index), functional capacity (e.g. 6 minute walk test), life style as well as psychosocial factors (e.g. smoking, diet, physical activity, health-related quality of life and depression). the data will be collected at baseline (i.e. before the intervention), and 6 and 12 months after the intervention started. the participants (n = 300) are patients diagnosed with coronary heart disease. the study group (n = 150) is recruited from participants of tulppa rehabilitation in three health care districts (pirkanmaa, south karelia, päijät-häme). the control group (n = 150) is recruited from two health care districts (turku and hyvinkää) that do not provide tulppa rehabilitation.


Eligibility criteria:
inclusion criteria: * study group: patients diagnosed with coronary heart disease taking part in the tulppa cardiac rehabilitation program at pirkanmaa, south karelia and päijät-häme health districts * control group: patients diagnosed with coronary heart disease, living in the area of turku or hyvinkää which are health districts that do not provide tulppa rehabilitation. exclusion criteria: * acute and severe mental health problems, alcohol abuse, major limitations in physical activities

Keywords: rehabilitation coronary heart disease cardiovascular diseases risk factors life-style changes efficacy
optic nerve perfusion following treatment with latanoprost versus brimionidin tartrate

Conditions: Glaucoma

Summary: this study aimed to evaluate the effects of topical latanoprost 0.005 % versus brimionidin tartrate 0.2% on perfusion of optic nerve head this prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral primary open angle glaucoma equally divided into two groups with 28 patients in each group

this study aimed to evaluate the effects of topical latanoprost 0.005 % versus brimionidin tartrate 0.2% on perfusion of optic nerve head this prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral poag equally divided into two groups with 28 patients in each group. the whole vd was increased and also increased in all four nasal, temporal, superior, and inferior quadrants around optic disc from the initial vessel density before treatment (p\<0.001) in both groups significantly with superior improvement in group (1) compared to group (2) that was statistically significant

Eligibility criteria:
inclusion criteria: * age more than 18 years newly diagnosed naive patients with poag exclusion criteria: * optic nerve lesions other than glaucomatous changes patients with previous glaucoma surgery

Keywords: latanoprost brimonidine
a study of rescure™ to treat covid-19 infection

Conditions: COVID; Covid-19; Corona Virus Infection; Sars-CoV2; Coronavirus-19; SARS Pneumonia; SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere

Summary: this is a phase i open-label interventional study which will test the efficacy of rescure™ in the treatment of patients with covid-19 infection.

in this phase i open-label interventional study we will test the efficacy of rescure™ in the treatment of patients with covid-19 infection. patients being treated will have severe respiratory symptoms that are at or near requiring the patient be placed on a ventilator.

Eligibility criteria:
inclusion criteria: 1. critically ill patients with sars from covid-19 infection on respirators or 2. patients with sars from covid-19 infection prior or after being placed on respirator 3. male or female patients 18 years of age and older exclusion criteria: 1. patients less than 18 years of age
negative pressure wound therapy in post-operative incision management

Conditions: Negative-Pressure Wound Therapy

Summary: the purpose of this study is to compare any good and bad effects of using the prevena incision management system to using the usual standard dry gauze approach. the prevena incision management system is a type of negative pressure wound therapy (npwt). npwt is a portable vacuum device made of a sponge-like foam that is applied over your incision to help draw fluid and debris out after surgery.


Eligibility criteria:
inclusion criteria: criteria for eligibility prior to surgery: * women of any bmi undergoing a laparotomy procedure for a presumed gynecologic malignancy, or morbidly obese (bmi ≥ 40) women undergoing a laparotomy for any indication * or women who are morbidly obese (bmi\>40) undergoing laparotomy for any indication * age ≥ 18 criteria for eligibility during surgery: * women of any bmi undergoing a laparotomy procedure for a presumed gynecologic malignancy, or morbidly obese (bmi ≥ 40) women undergoing a laparotomy for any indication * or women who are morbidly obese (bmi\>40) undergoing laparotomy for any indication * age ≥ 18 exclusion criteria: exclusion prior to surgery: * women undergoing panniculectomy at the time of laparotomy * women with sensitivity to silver exclusion during surgery: * women with laparotomy incisions left open due to case classification as "contaminated" or "dirty" * women with laparotomy incisions unable to be closed primarily due to tissue or fascial damage

Keywords: undergoing laparotomy 15-309
a study to assess the long-term safety of pharmaceutical grade synthetic cannabidiol oral solution in participants with prader-willi syndrome

Conditions: Prader-Willi Syndrome

Summary: the objective of this study is to assess the long-term safety and tolerability of cannabidiol oral solution (cbd) in participants with prader-willi syndrome.


Eligibility criteria:
inclusion criteria: 1. completed activities up to and including visit 10 (study completion) of ins011-16- 085. 2. participant and/or parent(s)/caregiver(s) fully comprehend the informed consent form and assent form, understand all study procedures, and can communicate satisfactorily with the investigator and study coordinator, in accordance with applicable laws, regulations, and local requirements. 3. if female, is either not of childbearing potential or practicing medically acceptable methods of birth control. 4. psychotropic treatment will be permitted if the participant has been on a stable dose during the ins011-16-085 and does not anticipate a dose change during the course of the study. 5. growth hormone treatment will be permitted if the participant has been on a stable dose during ins01-16-085. 6. any other treatment including thyroid hormones should be stable prior to entering the ins011-17-115 study. 7. in the opinion of the investigator, the parent(s)/caregiver(s) is (are) willing and able to comply with the study procedures and visit schedules, including venipuncture, and the visit schedules. exclusion criteria: 1. participant or parent(s)/caregiver(s) have commitments during the study duration that would interfere with attending all study visits. 2. experienced an anoxic episode related to study drug requiring resuscitation during the previous study. 3. uncontrolled type i and type ii diabetes. 4. developed an adverse event thought to be related to cbd in the previous study and the investigator determines that continuing treatment with cbd would not be in the best interest of the partient. 5. history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or other condition which would jeopardize safety or impact validity of results (per investigator). 6. currently taking felbamate. 7. compromised respiratory function or severe respiratory insufficiency. 8. pregnant or lactating female. 9. in the opinion of the investigator, the participant is unsuitable in any other way to participate in this study.
effect of texting and writing on grip and pinch strength

Conditions: Muscle Weakness Condition; Hand Grasp

Summary: texting and writing are common hand activities among college students. students tend to spend increasing hours of texting and writing for every day activities in addition to the academic assignments that are mainly on line and through distance education. the effect of such daily activities on hand grip and key pinch strength has not been studied among college students.

students will be recruited from physical therapy department of college of medical rehabilitation sciences after satisfying the inclusion and exclusion criteria. participants will be randomly assigned to one of the four groups (texting 10 minutes, texting 15 minutes, writing 10 minutes and writing 15 minutes). participants will be blinded to the outcome measures and the evaluator will be blinded to the participants assigned group. hand grip strength and key pinch strength will be the main outcome measures. participants demographics will be gathered in addition to recreational status, risk factors, pain body diagram and number of hours spent for texting and writing in every day life.

Eligibility criteria:
inclusion criteria: * active college student * healthy * willing to participate * using smart phones\& electronics * hand writing for \> 10 minutes/day exclusion criteria: * recent upper limbs injury (sprain\& strain) * chronic neurological disorder * carpal tunnel syndrome * de quervain's disease * diabetic neuropathy

Keywords: hand grip strength, key pinch, risk factors, students key pinch risk factors students
correlation between patient perception and findings on clinical examination in chronic obstructive pulmonary disease (copd) patients

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: this is a multi-center, prospective, non-interventional study that aims to evaluate in daily clinical practice the possible correlation between patient perception of the ability to perform morning activities and the physician's assessment during a regular physical exam in patients with chronic obstructive pulmonary disease (copd), group c and d.

correlation between patient perception of the ability to perform morning activities and findings on clinical examination in copd patients receiving inhaled combined therapy (corticosteroid/long acting ß2-agonist) - relief study

Eligibility criteria:
inclusion criteria: * diagnosis of chronic obstructive pulmonary disease (copd), group c and d according to gold guidelines, 2011 * receive inhaled combined therapy for copd (inhaled corticosteroid / long acting ß2-agonist); this treatment should have been initiated for at least one month before entering the study * current or past smokers, of at least 10 pack years exclusion criteria: * history of exacerbation of copd symptoms within the last month before visit 1, inclusive. * history of asthma or allergic rhinitis. * history of lung carcinoma or any other respiratory condition that may limit the airflow circulation.

Keywords: copd gold group c and d cdlm questionnaire visual scale - physician evaluation